+1 to PharmacoVig_BOS. Especially the point about "Re: FDA warning letters to — the subgrou..." — I have seen the same in my own experience with FDA warning letters to.

Want to share my personal experience related to FDA warning letters to since I think it might help others in a similar situation.

I started my GLP-1 journey in March 2025 at 277 lbs with metabolic syndrome. My telehealth provider prescribed semaglutide 0.25mg to start.

Now, 18 months later: I am down 57 lbs, my labs have normalized, and my sleep apnea has improved dramatically. The FDA warning letters aspect specifically was something that made a big difference in my journey.

This forum was my go-to resource throughout.

lisa_labSD — that is really helpful context on FDA warning letters to. Follow-up question: did you change anything about your diet at the same time?

I am in a similar situation (month 2) and trying to set realistic expectations.

To answer jennifer_SEA's question specifically:

From a clinical standpoint, FDA warning letters to is well-supported by the literature.

The short answer: follow the standard titration protocol and reassess at 4-6 weeks.

The longer answer involves pharmacokinetic considerations around steady-state concentrations, which I am happy to elaborate on if helpful.

Saving this for reference. Top-tier content.